A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer

Trial Profile

A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Ribociclib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 05 Apr 2017 Results of a pooled analysis assessing preliminary clinical activity in patients from three clinical trials (NCT01872260, NCT01857193 and NCT02088684), presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 19 Jan 2017 Planned End Date changed from 1 Sep 2019 to 1 Sep 2017.
    • 19 Jan 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top